Multidrug-resistant pulmonary tuberculosis
The Aurum Institute is involved in clinical research focused on rifampicin-resistant tuberculosis and pulmonary tuberculosis, with attention to treatment-resistant infection and recovery of lung function.
- Host-directed therapy
- Anti-inflammatory treatment
- Antimicrobial therapy
Its research activity also includes outcomes related to Mycobacterium tuberculosis eradication, pulmonary function, and measures of treatment response in resistant disease.
